Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Hormone therapy controversy raises drug safety issues

17.02.2005


The history of hormone therapy drugs – once thought of as almost magic pills to keep women healthy, vital and young – shows why it is so important to conduct research studies to identify the risks and benefits of drugs, say researchers from Wake Forest University Baptist Medical Center.



"The hormone therapy debate is one more example of a larger issue: are the medications that doctors prescribe safe, and do the benefits outweigh any risks?" said Michelle Naughton, Ph.D., lead author of an article in the current issue of Journal of Social Issues.

The researchers review the 75-year history of hormone therapy (HT), including the Women’s Health Initiative (WHI) research that found increased risk of breast cancer, dementia, heart attacks and strokes in women taking combination hormone therapy – and increased risk of strokes in women taking estrogen alone. Naughton and co-authors Alison Snow Jones, Ph.D., and Sally Shumaker, Ph.D., all from Wake Forest Baptist, examine why there has been so much controversy surrounding the research findings and why many women and physicians are reluctant to accept the "lost promise" of HT. HT gained popularity in the 1950s and 1960s and is considered the best treatment for hot flashes and night sweats, which affect as many as two-thirds of menopausal women in the United States. But HT was also marketed as a way women could retain a youthful appearance and stave off the aging process and was prescribed for prevention of heart disease and dementia.


What began as a therapy for bothersome menopausal symptoms that dissipate within a couple of years for most women, became a potential long-term therapy for the prevention and treatment of three of the most common health issues for women – heart disease, dementia and osteoporosis, write the authors. "The intent was good," said Naughton, an associate professor of public health sciences. "There was some evidence showing the drugs might be beneficial for heart disease and dementia," she said, "but the WHI, a large-scale, scientifically conducted clinical trial, found otherwise."

Yet even after the WHI research, which the authors say the Food & Drug Administration found to be definitive, controversy continues about the study results and about use of HT. "In the face of such strong evidence that, at a minimum, HT does not help the postmenopausal woman beyond the osteoporosis benefit … and can actually harm the aging woman, why has there been resistance among many physicians and women to changing beliefs and practice patterns?" the researchers ask. They conclude that the conflicting interests of women, physicians and drug companies played a role in the popularity of HT (at one time it was one of the most commonly prescribed drugs in the United States) and fuel the continued controversy. They examine the issue from the perspectives of the various stakeholders. For women in the United States, who can expect to live a third or more of their lives after menopause, the stakes are a higher quality of life through their later years. In spite of evidence to the contrary, some women continue to believe that hormone therapy will provide them with better health, the authors said.

Health care professionals are influenced by the needs of their patients and well as information provided by drug manufacturers. In addition, they make their decisions based on years of clinical experience with HT, and may be reluctant to change prescribing patterns based on research findings that small numbers of study participants suffered adverse affects. "Physicians have learned that hormone therapy does provide relief to their patients," the authors write. "How can a drug that does such immediate good, and that appeared to do such long-term good, be so wrong?"

For hormone manufacturers, the stakes are millions of dollars in revenue. HT revenues were reported to be about $2.5 billion a year prior to the WHI study and sales fell to $266 million in the first quarter of 2004. Drug companies work to identify and promote drugs that offer the most promise to patients, but also must consider benefits to their stockholders.

Naughton said the HT controversy, as well as recent controversy surrounding Vioxx and other pain medications, raise issues about drug safety. "Implications of these controversies are the need for better mechanisms for establishing drug safety and monitoring, including the reporting of negative as well as positive trials of new or approved drugs," she said.

Karen Richardson | EurekAlert!
Further information:
http://www.wfubmc.edu

More articles from Health and Medicine:

nachricht One gene closer to regenerative therapy for muscular disorders
01.06.2017 | Cincinnati Children's Hospital Medical Center

nachricht The gut microbiota plays a key role in treatment with classic diabetes medication
01.06.2017 | University of Gothenburg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can we see monkeys from space? Emerging technologies to map biodiversity

An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.

Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Quantum thermometer or optical refrigerator?

23.06.2017 | Physics and Astronomy

A 100-year-old physics problem has been solved at EPFL

23.06.2017 | Physics and Astronomy

Equipping form with function

23.06.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>